Rocket Pharmaceuticals

Yahoo Finance • 5 days ago

Fanconi Anemia Market Research Report 2025-2035: Competitive Growth Driven by Rocket Pharmaceuticals, Foresee, Merck, and Abeona as Gene Therapy and CRISPR-Based Innovations Expand

Company Logo **Fanconi Anemia Market Growth Driven by Genetic Research and Healthcare Investments**Fanconi Anemia (FA) is a rare genetic disorder impacting bone marrow's ability to produce blood cells, leading to pancytopenia and increase... Full story

Yahoo Finance • 17 days ago

Rocket Pharmaceuticals, Inc. Q3 Loss Decreases, Beats Estimates

(RTTNews) - Rocket Pharmaceuticals, Inc. (RCKT) revealed Loss for third quarter that decreased from last year and beat the Street estimates. The company's bottom line came in at -$50.33 million, or -$0.45 per share. This compares with -... Full story

Yahoo Finance • last month

ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Rocket (RCKT) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Rocket securities between Febru... Full story

Yahoo Finance • last month

Prothena Corporation plc (PRTA): A Bull Case Theory

This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: 10 High-Potential Small-Caps With Market Cap Under $1B. We came across a bullish thesi... Full story

Yahoo Finance • 2 months ago

Rocket Pharmaceuticals withdraws review application to FDA for RP-L102

[DNA] peterschreiber.media/iStock via Getty Images Rocket Pharmaceuticals (NASDAQ:RCKT [https://seekingalpha.com/symbol/RCKT]) reported that it has voluntarily withdrawn its biologics marketing application to the U.S. FDA for mozafancogen... Full story

Yahoo Finance • 3 months ago

Rocket Pharmaceuticals announces CFO resignation

[concept word CFO on cubes.close up of wooden elements,Business Concept.3D rendering on blue background.] * Rocket Pharmaceuticals (NASDAQ:RCKT [https://seekingalpha.com/symbol/RCKT]) said that its chief financial officer, Aaron Ondrey,... Full story

Yahoo Finance • 3 months ago

Rocket Pharmaceuticals stock rises as FDA lifts clinical hold on Danon disease program

Investing.com - Rocket Pharmaceuticals (NASDAQ:RCKT) shares surged 23.8% this week after the company announced the FDA lifted its clinical hold on the RP-A501 program for Danon disease. According to InvestingPro data, the stock remains sig... Full story

Yahoo Finance • 3 months ago

Goldman Sachs reiterates Sell rating on Rocket Pharmaceuticals stock

Investing.com - Goldman Sachs has reiterated its Sell rating and $2.00 price target on Rocket Pharmaceuticals (NASDAQ:RCKT) following the FDA’s decision to lift a clinical hold on the company’s pivotal Phase 2 study for Danon disease. The... Full story

Yahoo Finance • 3 months ago

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

(Reuters) -Rocket Pharmaceuticals said on Wednesday that the U.S. Food and Drug Administration has lifted the clinical hold on a mid-stage trial of its gene therapy, less than three months after it was halted due to a patient’s death. Roc... Full story

Yahoo Finance • 3 months ago

Lexeo Therapeutics stock price target lowered to $9 at H.C. Wainwright

Investing.com - H.C. Wainwright lowered its price target on Lexeo Therapeutics (NASDAQ:LXEO) to $9.00 from $15.00 on Friday, while maintaining a Buy rating on the stock. Currently trading at $4.79, LXEO appears undervalued according to Inv... Full story

Yahoo Finance • 3 months ago

Levi & Korsinsky Reminds Rocket Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 – RCKT

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to... Full story

Yahoo Finance • 3 months ago

DEADLINE ALERT for RCKT, DDD, TEM, RDDT: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

BENSALEM, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the d... Full story

Yahoo Finance • 3 months ago

DEADLINE ALERT for RCKT, TEM, and DDD: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, Aug. 11, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the... Full story

Yahoo Finance • 3 months ago

Biotech sector slips amid reported return of ousted FDA official

[FDA headquarters in Washington DC.] JHVEPhoto/iStock Editorial via Getty Images Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration vaccine regulator Vinay Prasad w... Full story

Yahoo Finance • 3 months ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Such investors are advised to contact Daniell... Full story

Yahoo Finance • 4 months ago

Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) Seeking Recovery for Investors – Contact Levi & Korsinsky

NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to... Full story

Yahoo Finance • 4 months ago

Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA’s Clinical Hold on Gene Therapy Trial – Hagens Berman

SAN FRANCISCO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat p... Full story

Yahoo Finance • 4 months ago

MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Rocket Pharmaceuticals class action lawsuit – captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.) – seeks to represent pu... Full story

Yahoo Finance • 4 months ago

Rocket Pharmaceuticals GAAP EPS of -$0.62 misses by $0.06

* Rocket Pharmaceuticals press release [https://seekingalpha.com/pr/20193932-rocket-pharmaceuticals-reports-second-quarter-2025-financial-results-and-highlights-recent] (NASDAQ:RCKT [https://seekingalpha.com/symbol/RCKT]): Q2 GAAP EPS of... Full story

Yahoo Finance • 4 months ago

Investors in Rocket Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before August 11, 2025 to Discuss Your Rights – RCKT

NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of RCKT during the class period listed are enco... Full story